<DOC>
	<DOCNO>NCT02329184</DOCNO>
	<brief_summary>The purpose study establish initial safety , tolerability , pharmacokinetics pharmacodynamics MYK-461 human subject . This sequential group , single ascending ( oral ) dose study NYHA Class I , II , III patient volunteer age 18-65 year .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability Preliminary Pharmacokinetics Pharmacodynamics MYK-461</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>Diagnosed HCM Normal leave ventricular ejection fraction ( LVEF ) NYHA class I , II III Inherited metabolic disorder , myocardial infiltration cardiofaciocutaneous syndrome ( e.g. , Noonan 's , Fabry 's ) . History clinically important atrial ventricular arrhythmia History positive human immunodeficiency virus ( HIV ) test and/or seropositive hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) ..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>